StageZero Life Sciences Ltd. (SZLS.TO)
| Previous Close | 0.0400 |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
ACCESSWIREStageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order
TORONTO, ON / ACCESSWIRE / July 9, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for ...
ACCESSWIREStageZero Life Sciences Announces Update on Failure to File Cease Trade Order
TORONTO, ON / ACCESSWIRE / May 23, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ...
- ACCESSWIRE
StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single ...
